Julie Oestreich, Pharm.D., Ph.D.

Assistant Professor

Department of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
986045 Nebraska Medical Center
Omaha, NE 68198-6045
402-559-2916 (Office)
402-559-5673 (Fax)
joestreich@unmc.edu

Teaching Activities:
Dr. Oestreich is the course coordinator for Pharmacogenomics (PHPR 685) and provides instruction in Pharmacotherapy (PHPR 674), Pharmaceutical Sciences (PHSC 670 and 672), and Applied Biochemistry (PHPS 514).

Research Activities/Interests: 
Dr. Oestreich's primary research interest is the variability of platelet function and response to antiplatelet agents. Dr. Oestreich’s lab uses ex vivo methods to study platelet activation, aggregation, and coagulation. The goal of this research is to personalize patient therapy so that protection from adverse cardiovascular events is balanced with bleeding risk.

Recent Publications:

  1. Oestreich JH, Ferraris SP, Steinhubl SR, and Akers WS. Pharmacodynamic interplay of the P2Y1, P2Y12, and TxA2 pathways in platelets: the potential of triple antiplatelet therapy with P2Y1 receptor antagonism. Thrombosis Research. 2012; http://dx.doi.org/10.1016/j.thromres. 2012.11.019.
  2. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, Mazer CD, Bridges CR, Despotis GJ, Jointer K, and Clough ER. 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. The Annals of Thoracic Surgery. 2012;94(5):1761-1781.
  3. Kelso ML and Oestreich JH. Traumatic brain injury: central and peripheral role of α7 nicotinic acetylcholine receptors. Current Drug Targets. 2012;13:631-636.
  4. Oestreich JH. Progress of antiplatelet pharmacogenomics. Current Drug Targets. 2011; 12:1848-1858.
  5. Oestreich JH and Dobesh PP. Platelet reactivity testing: an objective analysis of current capability. Acute Coronary Syndromes. 2011;10(2):55-62.
  6. Oestreich JH, Steinhubl SR, Ferraris SP, Akers WS. High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. Thrombosis and Haemostasis. 2011 May;105(5):927-930.
  7. Oestreich JH. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Current Opinion in Investigational Drugs. 2010 Mar;11(3):340-348.
  8. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. Journal of Clinical Pharmacology. 2010;50(1):27-35.
  9. Oestreich JH, Holt J, Dunn SP, Smyth SS, Campbell CL, Charnigo R, Akers WS, Steinhubl SR. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coronary Artery Disease. 2009 May;20(3):207-213.
  10. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thrombosis Research. 2008;121:527-534.

 

Julie Oestreich, Pharm.D., Ph.D.
Dr. Oestreich
;